Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Analysis of RCT (n=17,160) found, in those with multiple risk factors for atherosclerotic cardiovascular disease (ASCVD), the reduction in risk of CV death or hospitalisation for heart failure & the renal outcome for dapagliflozin did not differ from those with established ASCVD

Source:

Diabetes Care